Spotlight on Gynecology/Obstetrics
Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis During Pregnancy: Charting the Disease Course
StartActivity Details
0.25 Contact Hour(s)
Expires: February 27, 2022
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
- Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.
Activity Description
In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis
Faculty
Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA
Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi
Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Viela Bio
Vindico Medical Education Staff
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
0.25 Contact Hour(s)
Expires: February 27, 2022
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
- Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.
Activity Description
In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis
Faculty
Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA
Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi
Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Viela Bio
Vindico Medical Education Staff
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Gynecology/Obstetrics Presentations
Unlocking Epigenetic Secrets from the Womb: Therapeutic Options for Advanced and Recurrent Endometrial Cancer
StartActivity Details
Expires: April 8, 2022
Accredited By
Provided by Integrity Continuing Education, Inc.
Statement of Commercial Support
Supported by independent educational grants from Eisai, GlaxoSmithKline, and Merck Sharp & Dohme Corp.
Target Audience
This program is intended for medical oncologists, gynecologic oncologists, primary care physicians, advanced practice providers, emergency department physicians, and pharmacists involved in the management and treatment of patients with endometrial cancer (EC).
Learning Objectives
- Identifyboth preventable and inescapable risk factors that drive mortality rates in advanced and recurrent EC
- Select appropriate and individualized treatment approaches for each EC patient based genomic subtypes and molecular markers
- Developa strategy for identifying and addressing adverse events caused by immunotherapy and/or combination treatments
- Incorporatea patient-centric treatment approach that considers each woman’s well-being and quality of life
Activity Description
Previously hidden epigenetic alterations of a more malevolent and disordered nature can result in EC, the most common gynecologic malignancy in the United States. Recent unraveling of the molecular profile of EC and its tumor microenvironment has revealed the immunologic nature of this disease, showing that up to 91% of patients with advanced or recurrent EC have at least one genetic mutation that can serve as an actionable therapeutic target. Indeed, unlocking the epigenetic secrets of advanced and recurrent EC has shown this disease to be highly immunogenic, making this gynecologic cancer an ideal candidate for immunotherapy. Consequently, immunotherapy with immune checkpoint inhibitors (ICIs) are being researched as both monotherapy and in synergistic combinations with cytotoxic, hormonal, and targeted treatments for greater efficacy and improved survival outcomes.
In this case-based activity, clinicians will have the opportunity to navigate a simulated patient case, making clinical decisions about diagnosis, testing, and treatment when prompted. Feedback regarding decisions made will be provided as they move through the case.
Faculty
Professor of Medicine
Brown University
Director, Women’s Cancers & Hematology-Oncology Outpatient Clinics
Lifespan Cancer Institute
Director, Medical Oncology & Oncology Sexual Health Program
Rhode Island Hospital
Providence, Rhode Island
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology & Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Don S. Dizon, MD, FACP, FASCO
Consulting Fees: AstraZeneca, Clovis, Regeneron
Contracted Research: Bristol-Myers Squibb, Kazia, Pfizer, Tesaro
(Institutional funds)
Shannon N. Westin, MD, MPH, has no real or apparent conflicts of interest to disclose.
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of April 8, 2021 through April 8, 2022 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information for Questions About the Activity
For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.
Activity Details
Expires: April 8, 2022
Accredited By
Provided by Integrity Continuing Education, Inc.
Statement of Commercial Support
Supported by independent educational grants from Eisai, GlaxoSmithKline, and Merck Sharp & Dohme Corp.
Target Audience
This program is intended for medical oncologists, gynecologic oncologists, primary care physicians, advanced practice providers, emergency department physicians, and pharmacists involved in the management and treatment of patients with endometrial cancer (EC).
Learning Objectives
- Identifyboth preventable and inescapable risk factors that drive mortality rates in advanced and recurrent EC
- Select appropriate and individualized treatment approaches for each EC patient based genomic subtypes and molecular markers
- Developa strategy for identifying and addressing adverse events caused by immunotherapy and/or combination treatments
- Incorporatea patient-centric treatment approach that considers each woman’s well-being and quality of life
Activity Description
Previously hidden epigenetic alterations of a more malevolent and disordered nature can result in EC, the most common gynecologic malignancy in the United States. Recent unraveling of the molecular profile of EC and its tumor microenvironment has revealed the immunologic nature of this disease, showing that up to 91% of patients with advanced or recurrent EC have at least one genetic mutation that can serve as an actionable therapeutic target. Indeed, unlocking the epigenetic secrets of advanced and recurrent EC has shown this disease to be highly immunogenic, making this gynecologic cancer an ideal candidate for immunotherapy. Consequently, immunotherapy with immune checkpoint inhibitors (ICIs) are being researched as both monotherapy and in synergistic combinations with cytotoxic, hormonal, and targeted treatments for greater efficacy and improved survival outcomes.
In this case-based activity, clinicians will have the opportunity to navigate a simulated patient case, making clinical decisions about diagnosis, testing, and treatment when prompted. Feedback regarding decisions made will be provided as they move through the case.
Faculty
Professor of Medicine
Brown University
Director, Women’s Cancers & Hematology-Oncology Outpatient Clinics
Lifespan Cancer Institute
Director, Medical Oncology & Oncology Sexual Health Program
Rhode Island Hospital
Providence, Rhode Island
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology & Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Don S. Dizon, MD, FACP, FASCO
Consulting Fees: AstraZeneca, Clovis, Regeneron
Contracted Research: Bristol-Myers Squibb, Kazia, Pfizer, Tesaro
(Institutional funds)
Shannon N. Westin, MD, MPH, has no real or apparent conflicts of interest to disclose.
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of April 8, 2021 through April 8, 2022 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information for Questions About the Activity
For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.
On Topic Virtual Roundtable: Multidisciplinary Approaches and Thoughts on the Care of HER2+ Breast Cancer
StartActivity Details
Expires: February 28, 2022
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).
Learning Objectives
After participating in this activity, participants should be better able to:
- Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
- Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
- Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer
Activity Description
Treating patients with cancer is shifting from focusing solely on disease management to more of a patient-centered approach. This includes providing greater attention to psychosocial issues, quality of life, patient empowerment, and survivorship. To address these issues, many institutions are increasingly providing care by multidisciplinary teams. This activity aims to provide community-based clinicians with clinical recommendations to address challenging cases of HER2+ breast cancer via breast cancer experts.
Statement of Educational Need
Because of the volume of research and approvals regarding the use of anti-HER2-based therapies for patients with breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with HER2+ breast cancer need expert guidance to evaluate emerging data, use existing anti-HER2-based therapies safely and effectively, and plan strategies to appropriately integrate novel agents into practice when they become available, in consideration of patient needs and preferences.
Agenda
Introduction & The Role of HER2 in Breast Cancer
It Takes a Village: Optimizing the Breast Cancer Care Team
Treating Metastatic HER2+ Breast Cancer
Mitigating and Managing Adverse Events
Key Takeaways
Moderator
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas
Faculty
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Patient Advocates & Breast Cancer Survivors
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Conflict of Interest Policy/Disclosure Statement
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty
Joyce O'Shaughnessy, MD (Moderator)
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology,
AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech,
Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen
Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis,
Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche,
Seattle Genetics, Syndax Pharmaceuticals
Erika Hamilton, MD
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma
Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca,
Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics,
Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai
Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics
Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo
Marissa Marti, APRN, AGNP-C, AOCNP
Consulting Fees: Biotheranostics, Inc., Novartis, Puma
Biotechnology, Research to Practice, i3 Health
Patient Advocates & Breast Cancer
Survivors
Julia Maués
Consultant Fees: AstraZeneca, PUMA, Seattle Genetics,
Sanofi
Sheila McGlown
No relevant financial relationships to disclose.
Planning Committee
The following planning committee members have nothing to disclose except for
the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Accreditation Statement
In support
of improving patient care, this activity has been planned and
implemented by University of Nebraska Medical Center and Bio
Ascend. University of Nebraska Medical Center is jointly accredited by
the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: February 28, 2022
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).
Learning Objectives
After participating in this activity, participants should be better able to:
- Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
- Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
- Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer
Activity Description
Treating patients with cancer is shifting from focusing solely on disease management to more of a patient-centered approach. This includes providing greater attention to psychosocial issues, quality of life, patient empowerment, and survivorship. To address these issues, many institutions are increasingly providing care by multidisciplinary teams. This activity aims to provide community-based clinicians with clinical recommendations to address challenging cases of HER2+ breast cancer via breast cancer experts.
Statement of Educational Need
Because of the volume of research and approvals regarding the use of anti-HER2-based therapies for patients with breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with HER2+ breast cancer need expert guidance to evaluate emerging data, use existing anti-HER2-based therapies safely and effectively, and plan strategies to appropriately integrate novel agents into practice when they become available, in consideration of patient needs and preferences.
Agenda
Introduction & The Role of HER2 in Breast Cancer
It Takes a Village: Optimizing the Breast Cancer Care Team
Treating Metastatic HER2+ Breast Cancer
Mitigating and Managing Adverse Events
Key Takeaways
Moderator
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas
Faculty
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Patient Advocates & Breast Cancer Survivors
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Conflict of Interest Policy/Disclosure Statement
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty
Joyce O'Shaughnessy, MD (Moderator)
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology,
AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech,
Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen
Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis,
Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche,
Seattle Genetics, Syndax Pharmaceuticals
Erika Hamilton, MD
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma
Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca,
Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics,
Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai
Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics
Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo
Marissa Marti, APRN, AGNP-C, AOCNP
Consulting Fees: Biotheranostics, Inc., Novartis, Puma
Biotechnology, Research to Practice, i3 Health
Patient Advocates & Breast Cancer
Survivors
Julia Maués
Consultant Fees: AstraZeneca, PUMA, Seattle Genetics,
Sanofi
Sheila McGlown
No relevant financial relationships to disclose.
Planning Committee
The following planning committee members have nothing to disclose except for
the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Accreditation Statement
In support
of improving patient care, this activity has been planned and
implemented by University of Nebraska Medical Center and Bio
Ascend. University of Nebraska Medical Center is jointly accredited by
the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo.
Contact Information for Questions About the Activity
info@bioascend.com
Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis in the Postpartum Period: Lactation and Treatment Considerations
StartActivity Details
0.25 Contact Hour(s)
Expires: February 27, 2022
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objective
Upon successful completion of the activity, participants should be better able to:
- Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.
Activity Description
In this Curbside Consult, Drs. Patricia Coyle and Clyde Markowitz will discuss latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with multiple sclerosis during postpartum/lactation.
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis
Faculty
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA
Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, Sanofi/Genzyme, Teva
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Viela Bio
Vindico Medical Education Staff
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
0.25 Contact Hour(s)
Expires: February 27, 2022
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objective
Upon successful completion of the activity, participants should be better able to:
- Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.
Activity Description
In this Curbside Consult, Drs. Patricia Coyle and Clyde Markowitz will discuss latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with multiple sclerosis during postpartum/lactation.
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis
Faculty
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA
Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, Sanofi/Genzyme, Teva
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Viela Bio
Vindico Medical Education Staff
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Multiple Sclerosis in Women: Adaptation of Management Strategies for Family Planning and Beyond–Multiple Sclerosis During Pregnancy: Charting the Disease Course
StartActivity Details
0.25 Contact Hour(s)
Expires: February 27, 2022
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
- Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.
Activity Description
In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis
Faculty
Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA
Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi
Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Viela Bio
Vindico Medical Education Staff
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
0.25 Contact Hour(s)
Expires: February 27, 2022
Accredited By
This continuing education activity is provided by
Target Audience
The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Incorporate understanding of protective effects of pregnancy in women with MS, including the marked changes in disease activity during the 3 trimesters.
- Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.
Activity Description
In this Curbside Consult, Drs. Patricia Coyle and Maria K. Houtchens will discuss the effects of pregnancy in women with multiple sclerosis, as well as the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in pregnant women with MS.
Activity Chair
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis
Faculty
Maria K. Houtchens, MD, MMs
Associate Professor of Neurology
Harvard Medical School
Director, Clinical Care
Director, Women’s Health Program
Brigham and Women’s Hospital
Boston, MA
Disclosures:
Consulting Fee: Biogen, EMD Serono, Novartis, Roche, Sanofi
Genzyme
Contracted Research: Biogen, EMD Serono, Roche, Sanofi Genzyme
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme,
Mallinckrodt, Novartis, Viela Bio
Vindico Medical Education Staff
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Managing Cardiovascular Disease Risk in Women
StartActivity Details
ABIM MOC
Expires: September 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is gynecologists, obstetricians, family practice physicians, internists, and other health care professionals involved in the management of patients at risk for cardiovascular disease (CVD).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Describe traditional and female-predominant factors that contribute to CVD risk in women.
- Outline available screening tools and guidelines to identify women with elevated CVD risk.
- Review available clinical evidence to select treatment for patients who may benefit from reduction of LDL cholesterol for decreased risk of adverse CVD outcomes.
- Assess evidence-based strategies to reduce triglyceride levels in patients who may benefit from further CVD risk reduction.
- Define approaches to improve patient communication and education to increase awareness of CVD risks in women and the importance of interventions to reduce risk.
Activity Description
Cardiovascular disease is the leading cause of death globally, and women are disproportionately affected, with higher morbidity and mortality rates than men. This trend has continued despite recent advances in awareness campaigns, gender-based guidelines, as well as available therapies. In the United States, CVD accounts for approximately 1 of every 5 female deaths, with almost 300,000 deaths in women each year. In addition to traditional cardiovascular risk factors, women often carry several nontraditional risk factors, many of which are related to pregnancy, hormonal influences, or comorbid disorders. Furthermore, women are less likely to receive guideline-recommended diagnostic testing and therapies. The faculty of this CME activity will address CVD risk factors, appropriate screening, as well as recent advances in management to improve outcomes and reduce CVD mortality.
Agenda
Defining and Recognizing Cardiovascular Disease Risk in Women
Martha Gulati, MD, MS, FACC, FAHA, FASPC
Reducing ASCVD Risk With Further Advances in Lipid-Lowering Therapy
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Clinical Cases
Martha Gulati, MD, MS, FACC, FAHA, FASPC, and Erin D. Michos, MD, MHS, FACC,
FAHA, FASE, FASPC
Faculty
Activity Co-Chairs:
Professor of Medicine
Chief of Cardiology, University of Arizona College of Medicine – Phoenix
Editor-in-Chief, CardioSmart for the American College of Cardiology
Phoenix, AZ
Disclosure: No relevant financial relationships to disclose.
Associate Professor of Medicine & Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosure: No relevant financial relationships to disclose.
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above which is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge Maintenance of
Certification (MOC) points in the American Board of Internal Medicine's
(ABIM) MOC program. It is the CME activity provider's responsibility to
submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Amarin Pharma Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
ABIM MOC
Expires: September 29, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is gynecologists, obstetricians, family practice physicians, internists, and other health care professionals involved in the management of patients at risk for cardiovascular disease (CVD).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Describe traditional and female-predominant factors that contribute to CVD risk in women.
- Outline available screening tools and guidelines to identify women with elevated CVD risk.
- Review available clinical evidence to select treatment for patients who may benefit from reduction of LDL cholesterol for decreased risk of adverse CVD outcomes.
- Assess evidence-based strategies to reduce triglyceride levels in patients who may benefit from further CVD risk reduction.
- Define approaches to improve patient communication and education to increase awareness of CVD risks in women and the importance of interventions to reduce risk.
Activity Description
Cardiovascular disease is the leading cause of death globally, and women are disproportionately affected, with higher morbidity and mortality rates than men. This trend has continued despite recent advances in awareness campaigns, gender-based guidelines, as well as available therapies. In the United States, CVD accounts for approximately 1 of every 5 female deaths, with almost 300,000 deaths in women each year. In addition to traditional cardiovascular risk factors, women often carry several nontraditional risk factors, many of which are related to pregnancy, hormonal influences, or comorbid disorders. Furthermore, women are less likely to receive guideline-recommended diagnostic testing and therapies. The faculty of this CME activity will address CVD risk factors, appropriate screening, as well as recent advances in management to improve outcomes and reduce CVD mortality.
Agenda
Defining and Recognizing Cardiovascular Disease Risk in Women
Martha Gulati, MD, MS, FACC, FAHA, FASPC
Reducing ASCVD Risk With Further Advances in Lipid-Lowering Therapy
Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Clinical Cases
Martha Gulati, MD, MS, FACC, FAHA, FASPC, and Erin D. Michos, MD, MHS, FACC,
FAHA, FASE, FASPC
Faculty
Activity Co-Chairs:
Professor of Medicine
Chief of Cardiology, University of Arizona College of Medicine – Phoenix
Editor-in-Chief, CardioSmart for the American College of Cardiology
Phoenix, AZ
Disclosure: No relevant financial relationships to disclose.
Associate Professor of Medicine & Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosure: No relevant financial relationships to disclose.
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above which is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 1.25 Medical Knowledge Maintenance of
Certification (MOC) points in the American Board of Internal Medicine's
(ABIM) MOC program. It is the CME activity provider's responsibility to
submit participant completion information to ACCME for the purpose of
granting ABIM MOC credit.
Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 80% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Amarin Pharma Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Incorporating Recently Approved Targeted Agents, Emerging Combinations, and Genetic Testing for the Optimal Management of Patients with Ovarian Cancer
StartActivity Details
Expires: April 18, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.
Learning Objectives
After participating in this activity, participants should be better able to:
- Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
- Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
- Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
- Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer
Activity Description
This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.
Statement of Educational Need
Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.
Agenda
- Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
- Integrating Genetic Testing Into Clinical Practice
- Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
- Summary
Faculty
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio
Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through April 18, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com
Activity Details
Expires: April 18, 2021
Accredited By
The University of Nebraska Medical Center, Center for Continuing Education
Target Audience
The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.
Learning Objectives
After participating in this activity, participants should be better able to:
- Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
- Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
- Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
- Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer
Activity Description
This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.
Statement of Educational Need
Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.
Agenda
- Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
- Integrating Genetic Testing Into Clinical Practice
- Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
- Summary
Faculty
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio
Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.
Conflict of Interest Policy/Disclosure Statement
Faculty and Planning Committee Disclosures
As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.
Accreditation Statement
Continuing Education
The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through April 18, 2021.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.
Contact Information for Questions About the Activity
cme@bioascend.com